NeGIO Therapeutics SA
1.5 FTENeGIO Therapeutics reported total assets of €4.76m at the end of the 2025 financial year (annual accounts filed with the NBB on 26 May 2026), with 1.5 full-time equivalent.
The score of NeGIO Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Equity -41 % Total assets -43 % Headcount (avg FTE) -42 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
NeGIO Therapeutics's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 26 May 2026
- Year ended 31 Dec 2024filed on 30 Jul 2025
- Year ended 31 Dec 2023filed on 28 Aug 2024
NeGIO Therapeutics's financial analysis
- Solvency99.7%sector median: 46.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of NeGIO Therapeutics
NeGIO Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0799.822.012
- VAT number
- BE0799822012
- Peppol
- Registered · 0208:0799822012 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 22 Mar 2023
- Registered office
- 6041 Charleroi
- Size
- Micro · 1.5 FTE
- Latest accounts
- 2025 · filed on 26 May 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
NeGIO Therapeutics (SA) has been based in Charleroi since 2023, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of 607,875 € and equity of €4.75m; its revenue is not published. With 1.5 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 99.7%, above the median of its sector (46.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to NeGIO Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- Curavac Europe Manufacture of basic pharmaceutical products Rixensart · balance sheet €2.53m
- Verbert Manufacture of pharmaceutical preparations Antwerp · balance sheet €2.70m
- Lifrank Manufacture of basic pharmaceutical products Wingene · balance sheet €4.07m
- GRNR Invest Manufacture of basic pharmaceutical products Zemst · balance sheet €2.26m
- FASE Manufacture of pharmaceutical preparations Nazareth-De Pinte · balance sheet €2.45m
- Société d’Études, Commercialisation et Réalisation Manufacture of basic pharmaceutical products Anderlecht · balance sheet €1.70m
- XpressBioX Manufacture of basic pharmaceutical products Herstal · balance sheet €8.92m
- Thymolux Manufacture of basic pharmaceutical products Marche-en-Famenne · balance sheet €6.46m
Frequently asked questions about NeGIO Therapeutics
What is the revenue of NeGIO Therapeutics?
NeGIO Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of NeGIO Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0799822012 for NeGIO Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0799.822.012.
Where is the registered office of NeGIO Therapeutics?
According to the CBE register, the registered office of NeGIO Therapeutics is in 6041 Charleroi.
What is the equity of NeGIO Therapeutics?
At the close of the 2025 financial year, the equity of NeGIO Therapeutics amounts to 4,751,137 €, a solvency of 99.7% of total assets.
How many people work at NeGIO Therapeutics?
1.5 full-time equivalents on average according to the 2025 social balance sheet.
Who manages NeGIO Therapeutics?
The register lists 2 active mandates at NeGIO Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of NeGIO Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →